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Blood Glucose Monitoring: At a glance 
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Lecturer, Adult Nursing, Northumbria University 
 
 
 
Diabetes Mellitus: 
Diabetes Mellitus is a condition that results in elevated blood glucose levels (hyperglycaemia); 
continued elevation can contribute to progressive micro and macro vascular complications 
leading to renal, nerve and ocular damage, representing a significant contributor to morbidity 
and mortality (Bilous, Donnelly & Williams, 2010). Currently there are over 3 million people 
This article will:  
 Introduce Diabetes Mellitus Types 1 and 2 
 Give rationale to the importance of blood glucose monitoring as a fundamental nursing skill 
especially for those nursing people with diabetes 
 Support your understanding of how the human body regulates blood glucose 
 Identify correct blood glucose ranges and those which may give cause for concern 
 Recognise how to measure blood glucose accurately 
 Provide a ‘how to’ guide on monitoring blood glucose using a glucometer   
 Use contemporary evidence-based practice to underpin blood glucose monitoring practice 
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(aged 18-99) diagnosed within the UK representing a population prevalence of 5.9%; 1 in 17 
adults has diabetes Mellitus (IDF, 2017). 
Type 1 Diabetes Mellitus (T1DM) represents approximately 10% of cases. The origin of the 
condition being autoimmune in nature, arising from the complete destruction of insulin 
secreting beta cells within the pancreas. Type 2 diabetes Mellitus (T2DM) accounts for the 
remaining 90% of cases and results from the reduced effective action of insulin. Eventually, 
leading to insufficient level of insulin production, to sustain appropriate blood glucose levels. 
T2DM is caused by a combination of genetic and ethnic predispositions, but predominantly 
lifestyle factors such as obesity and lack of physical exercise. Incidence is further correlated 
with increasing age (Holt, Kumar & Watkins, 2015).  
Gestational diabetes mellitus (GDM) manifests with a degree of glucose intolerance with onset 
or first recognition in pregnancy. Individuals affected by GDM have an increased risk of 
developing diabetes after pregnancy (Buchanan et al, 2007). 
There are several subtypes of diabetes outside T1DM, T2DM and GDM, including but not 
limited to genetic defects leading to diabetes, idiopathic diabetes (presenting with no 
underlying autoimmune cause), endocrinopathies, or drug and chemical induced diabetes. For 
these reasons, and the potentially mixed picture of diagnosis, it is less important to label the 
type of diabetes than it is to understand the mechanisms and importance of hyper and hypo 
glycaemia and treat accordingly (American Diabetes Association, 2013).  
Rationale:  
The measurement of blood glucose provides information on the effectiveness of blood glucose 
metabolism and guides interventions to achieve optimal glucose control within the body.  
Glucose is a monosaccharide and is an essential fuel for the brain and other body cells formed 
as an end product of carbohydrate digestion (Maughan, 2008). Glucose is either metabolised 
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to produce energy or is stored in the muscles and liver as glycogen. Changes in glucose level 
after absorption of carbohydrate is termed the ‘glycaemic response’ (Sanders, 2016; Maughan, 
2008). Regulation of normal glucose metabolism is shown in Figure 1.  
The measurement of blood glucose is a key self-care activity for people with diabetes and has 
been shown to positively correlate with improved long –term glycaemic control (Shaji et al 
2013; Shrivastava, Shrivastava and Ramasamy, 2013) and can function as a cue to action in 
diabetes self-management (Brackney, 2018).     
The measurement of blood glucose is also a key nursing assessment for individuals:  
 With T1DM and T2DM 
 People with diabetes who have recently commenced or changed dosages of medication 
to increase insulin levels 
 People with diabetes undergoing surgery 
 People who are acutely sick  
 In an emergency where consciousness level may be affected by low blood glucose 
(adapted from Delves-Yates, 2018a) 
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Figure 1: Regulation of normal glucose metabolism  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference: Adapted from Boore et al, (2018) 
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Point of care testing for blood glucose levels is managed with the use of bedside finger prick 
testing. Using this approach, capillary blood glucose monitoring provides immediate results of 
hypo and hyperglycaemia (Dougherty and Lister, 2015). In the past, urine test strips were 
utilised however, accurate measurements relied on stable renal function making the test 
potentially unreliable (Holt, 2014).  
Target blood glucose ranges 
Normal target ranges:  
 Fasting plasma glucose level of 5-7 mmol/litre and 
 Plasma glucose level of 4-7 mmol/litre before meals at other times of day 
(NICE, 2015a) 
Hyperglycaemia:  
 Random plasma glucose of more than 11 mmol/litre (NICE, 2015b) 
Hyperglycaemia describes any blood glucose concentration that is higher than recognised 
target ranges (Patton and Thibodeau, 2015). Prolonged hyperglycaemia can result in damage 
Learning Point:  
Type 1 diabetes results in an absolute absence of insulin therefore blood glucose levels continue to 
rise because glucose cannot enter cells to be metabolised and produce energy; excess glucose 
cannot be stored as glycogen. These individuals require insulin injections every day. 
 
Type 2 diabetes causes cells to be less responsive to insulin and/or reduces insulin production by 
the pancreas; therefore, glucose entry into the cell is reduced resulting in increased blood glucose 
levels. Individuals may take medications to increase insulin production, to make cells more receptive 
to insulin or ultimately, may require injectable insulin 
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to many organs of the body leading to renal failure, blindness or gangrene resulting in 
amputation (Boore, Cook and Shepherd, 2018).  
Acute hyperglycaemia occurs when the body cannot utilise glucose due to insufficient or 
complete lack of insulin production. This causes the body to generate glucose via 
glycogenolysis (glycogen breakdown), lipolysis (fat breakdown) and gluconeogenesis (glucose 
derived from substrates such as lactate, glycerol and glucogenic amino acids). Blood glucose 
rises further, the person is effectively starving in a sea of plenty (Dean et al, 2004). Fatty acid 
metabolites know as ketone bodies, accumulate from this process, resulting in Ketoacidosis. 
Ketones are observed in the blood and urine (Marieb and Hoehn, 2015; Patton and Thibodeau 
2015). Symptoms of hyperglycaemia are summarised in table 1.  
Causes:                                                      
 Inadequate doses of insulin 
 Infection 
 Stress 
 Surgery 
 Medications (steroids, benzodiazepines)  
 Various in nutritional intake 
 Individuals receiving enteral / parenteral feeding  
 Critical illness 
(Marieb and Hoehn, 2015)    
Table 1: Symptoms  
Gastrointestinal  Nausea 
Vomiting 
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Abdominal pain 
Hunger 
Adrenergic ‘Fight or flight response’ 
 
Respiratory Tachypnoea 
Renal  Glycosuria (excess glucose in urine) 
Polyuria (and dehydration) 
Polydipsia  
Electrolyte imbalance Excess ketones (from fat metabolism) 
Hypokalaemia 
Hyponatraemia 
 
Liver and adipose tissue Acetone breath 
Cardiovascular Cardiac irregularities 
Central Nervous System CNS depression – drowsiness  
Coma 
(Adapted from Marieb and Kohen, 2015; Holt, Kumar and Watkins, 2015) 
 
 
 
 
 
 
Learning Point: Diabetic Ketoacidosis (DKA) 
 DKA results from severe hyperglycaemia and is a potentially life-threatening medical 
emergency 
 DKA requires high intensity nursing within high dependency / critical care units 
 In DKA urine will test positive for ketones and plasma ketones will be elevated  
 DKA requires urgent hospital treatment with insulin, fluid and usually potassium 
replacement 
 DKA leads to electrolyte imbalance due to excessive acidosis therefore close 
monitoring of electrolytes is required 
 DKA may be the presenting feature of newly diagnosed T1DM  
(Holt, Kumar and Watkins, 2015) 
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Hypoglycaemia:  
 Random plasma glucose of less than 4 mmol/litre  
Hypoglycaemia occurs when blood glucose levels fall resulting in inadequate energy available 
to the brain leading to abnormal behaviour - sometimes mistaken for drunkenness (Patton and 
Thibodeau, 2015). If prolonged the individual may lose consciousness and if not treated may 
die (Boore, Cook and Shepherd, 2018) 
 
 
 
 
 
 
The symptoms of hypoglycaemia are outlined in table 2.  
 
STOP 
 and think:  
4 is the floor 
Learning Point: Hyperosmolar Hyperglycaemic Syndrome (HHS) 
 HSS presents as extreme levels of hyperglycaemia without 
significant acidosis or ketones in people with T2DM (>40 mmol/l) 
 Ketones may not be present as people with T2DM may still produce 
low levels of insulin 
 May develop over weeks due to illness or dehydration 
 Management is similar to that of DKA although less likely to require 
potassium replacement but may need sub cut heparin to prevent 
thrombotic complications 
 Carries a higher mortality rate than DKA 
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Causes:  
 Inadvertent insulin or sulphonylurea overdose (sulphonylureas work by increasing 
endogenous insulin production in the person with type 2 diabetes) or in response to a 
recent change in dose  
 Missed or inadequate meal 
 Unexpected exercise 
 Error in timing of dosage 
 
Table 2: Symptoms  
Central nervous system   Headache 
 Confusion 
 Concentration difficulties 
 Changes is personality 
Cardiovascular  Palpitations 
Gastrointestinal  Hunger 
 Nausea 
 Belching 
Adrenergic  Sweating  
 Anxiety 
(Holt, Kumar & Watkins, 2015) 
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Hypoglycaemia treatment (NICE, 2018):  
Mild – moderate hypoglycaemia:  
 10-20g glucose given by mouth either in liquid form (such as GlucoGel®) or as 
granulated sugar / sugar lumps / 4-5 Jelly Babies 
 Repeat after 10-15 minutes 
 After initial treatment a snack providing sustained carbohydrate release will minimise 
rebound hypoglycaemia 
o Alternatively:  
 10g of glucose is obtained from 2 teaspoons of sugar / 3 sugar lumps 
and also from non-diet drinks i.e.: 100ml Coca-Cola®.  Note that the 
carbohydrate content of some glucose drinks is currently subject to 
change – check the label 
Severe hypoglycaemia (causing unconsciousness):  
 Glucagon can be given by injection, which increases plasma glucose by mobilising 
glycogen stored in the liver.  
 Give carbohydrate as soon as possible to restore liver glycogen stores 
 Glucagon may be prescribed for use in an emergency.  
 Alternatively, 20% glucose intravenous infusion can be given via a large gauge needle. 
10% glucose may also be used. 50% glucose is not recommended due to potential 
extravasation injury.  
 Blood glucose should be monitored closely, especially if there has been an overdose 
with long acting insulin or is due to an oral antidiabetic drug as hypoglycaemic effects 
may persist for many hours. 
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It is important to note that people with T1DM may become increasingly unaware that they are 
experiencing a hypoglycaemic episode as the number of episodes they experience increases. 
This is termed ‘hypo unawareness’. People with T1DM should be assessed for their awareness 
of hypoglycaemia at each annual review with their doctor (NICE, 2015a). 
Careful consideration must be given to the management of people with diabetes undergoing 
surgery as outlined in table 3.  
Table 3: Management of people with diabetes mellitus undergoing surgery:   
Target group Plan 
Well controlled T2DM   Omit oral hypoglycaemic agent (if 
taken) on morning of planned 
surgery 
 Monitor plasma glucose 
 List first thing in the morning 
 Encourage eating and drinking 
within 1 hour  
People on insulin / T1DM / Major elective 
surgery 
 Blood glucose control should be 
optimised prior to surgery with 
referral to a specialist team if needed 
 Maintain blood glucose levels 
between 6-10mmol/l – regular 
monitoring of plasma glucose levels 
required 
 Intra-operative management 
achieved with intravenous insulin, 
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glucose and potassium (variable rate 
intravenous insulin infusion VRIII) 
 Consider continuation of long acting 
insulin alongside VRIII in peri-
operative period 
 Measure electrolytes once daily 
 Conversion to usual insulin regime 
once eating and drinking normally 
 Give first dose of subcutaneous 
insulin and a meal then discontinue 
VRIII 
 Person should be monitored 
carefully for hypo/hyperglycaemia  
 
Reference: adapted from Holt, Kumar and Watkins, (2015) 
 
 
Blood Glucose Measurement:  
There are many devices available for ‘point of care’ (POC) testing. Several factors should be 
considered in the selection of meters, testing strips and lancets including:  
 Assurance that the meter has been designed for use by non-laboratory staff 
 Is the device suitable for the given setting (i.e.: critical care, in an ambulance, GP 
surgery)? 
 Is the lancet / meter single or multiple use? 
13 
 
 Does the design of the equipment meet the needs of the user?  
 Is the device CE marked?  
Staff must be appropriately trained in the use of blood glucose meters, have an awareness of 
potential sources of error, be able to give advice and interpret results and have their competence 
recorded appropriately with access to regular updates. There must be a standard operating 
procedure / local policy in place to ensure testing is carried out in line with best available 
evidence and with access to the manufacturer’s guidance on the use of all blood glucose 
monitoring equipment (MHRA, 2013) 
Equipment:  
 Personal protective equipment (non-sterile gloves, apron) 
 Blood glucose meter 
 Single use lancet 
 Test strips 
 Cotton wool / low linting gauze 
 Sharps box 
 Control solution 
 (Delves-Yates 2018b) 
Table 4 outlines the correct procedure to perform blood glucose monitoring.  
Table 4: ‘How to’ perform blood glucose monitoring  
Step Procedure Rationale 
1 Turn on the machine and ensure correct date and 
time are displayed and that there is adequate 
 To ensure safety 
 To ensure accuracy of 
result recorded 
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battery. Scan operator ID if required as per local 
policy 
2 Ensure the unit of measurement is mmol/L  To ensure accurate 
measurement 
3 Ensure equipment set up, this may vary 
according to the device or if automated systems 
are used. Always follow manufacturer guidelines 
and local policy. Checks may include: 
 Test strips are in date and have not been 
left exposed to air 
 The monitor and strips are calibrated 
together 
 Quality control testing is checked and 
carried out if required as per local policy 
and documented 
 Meter was decontaminated after previous 
use 
 The screen and display are intact  
 To minimise failure of 
device / equipment 
4 Identify the individual verbally and check against 
the wrist band 
 To ensure correct person 
is tested 
 To gain consent for the 
procedure 
5 Select an appropriate site, consider:  
 Skin condition – site should be well 
perfused and free of callouses 
 Rotating sites and 
avoiding previous 
puncture areas reduces 
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 Avoid burns, cuts, scars, bruises, rashes 
 Avoid areas that have been subject to 
continual testing 
 Usual sites include the distal segment of 
the 3rd or 4th finger 
soreness and callous 
formation 
 Tips, pads of fingers and 
the index finger should 
be avoided as they have 
a dense supply of nerve 
endings and testing may 
be more painful 
6 Ask person to sit / lie down  Ensures safety by 
minimising risk of 
fainting 
7 Ask the person to wash hands with soap and 
water and dry with low-linting gauze 
 Removes any 
contaminant which may 
give misleading 
readings 
8 Practitioner to wash hands and don gloves and 
observe universal precautions as per local policy 
 To ensure safety by 
minimising cross 
infection 
9 Take a single use lancet and ensure correct 
setting is used if depth setting can be adjusted 
 Single use lancets 
minimise cross 
contamination and limit 
needle stick injury 
 Adjusting the depth 
setting ensures minimal 
discomfort 
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10 Remove the device cap if present; activate the 
lancet as per manufacturer’s guidance at the 
selected site. Utilise the side of the finger. Rotate 
sites 
Single use devices should be used in the in-
patient setting to avoid cross contamination. In 
the persons own environment a reusable device 
may be used 
If there is difficulty obtaining the blood sample, 
‘milking’ from the palm of the hand will increase 
droplet size, do not milk the finger alone 
 The side of the finger is 
less sensitive and is 
easier to obtain blood 
from 
 Sites are rotated to avoid 
infection, callous 
formation and to 
minimise pain 
 Milking the finger alone 
can cause contamination 
of the sample by 
interstitial fluid leading 
to a low reading 
11 Dispose of the lancet as per local policy  To minimise cross 
contamination 
 To minimise risk of 
sharp injury 
12 Insert the test strip into the blood glucose meter. 
Ensure meter is ready for droplet. Apply the first 
drop of blood and ensure the window is entirely 
covered with blood 
 Inadequately filled strips 
leads to inaccurate 
results or error reports 
13 Apply gauze and pressure to puncture site, 
monitor for excessive bleeding 
 To ensure safety 
 To minimise bleeding 
14 Remove gloves and apron, dispose of as per local 
policy, carry out hand hygiene as per local policy 
 To prevent infection 
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15 Document result and sign as per local policy  To ensure accurate 
record keeping 
16 Dock the machine / return the machine to its 
usual location 
 To log centralised 
records 
 To charge battery 
 To ensure machine is 
located in a 
predesignated area for 
further use 
17 Report any results outside of normal ranges  To ensure changes in 
blood glucose are 
treated appropriately to 
maximise glycaemic 
control 
18 Ensure the person is comfortable and receiving 
appropriate care 
 To ensure safety 
 To maximise 
satisfaction 
Reference: Adapted from Dougherty and Lister (2015) 
Errors in results:  
Potential sources of error include:  
 Incorrect meter calibration 
 Poor meter maintenance 
 Incorrect operator technique 
 Inadequate quantity of blood on test strip (gives false low readings) 
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 Out of date / improperly stored test strips (give false low readings) 
 Potential for error in low blood glucose range 
 Contamination of the sample may arise from substances present on the test-finger:  
o Alcohol gel or wipes used to clean the finger 
o Newspaper print, perfumes, hand creams, hairspray, hair gel  
o Residues of food and drink  
(Dougherty and Lister, 2015; Hortensius et al 2011; Trend UK, 2017) 
Interferences and contraindications to POC testing are detailed in table 5.  
Table 5: Contraindications / interferences in POC testing:  
Contra-indication Example 
Dialysis treatment  Some fluids may contain Maltose which can 
interfere with test strip methodology 
Peripheral circulatory failure Severe dehydration, DKA, hypotension, 
shock, peripheral vascular disease 
Severe dehydration Vomiting or diarrhoea, diuretics, 
uncontrolled diabetes 
Variations in blood oxygen tension People receiving intensive oxygen therapy 
High concentrations of non-glucose 
reducing substances in the blood 
Intravenous infusion of ascorbic acid 
High bilirubin values Jaundice 
Extremes of haematocrit Neonatal blood samples, pregnancy 
Hyperlipdaemia Total parenteral nutrition, hyperlipidaemia 
Reference: MHRA (2013) 
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Monitoring and reporting  
Accurate records of blood glucose monitoring are essential to ensure safety. Records should 
include results, test strip lot number, meter maintenance records, calibration and quality control 
testing, patient and operator identity and battery change (MHRA, 2013). Technology is now 
available to utilise wireless devices for POC testing which allow electronic data capture and 
documentation of results, device testing and operator identification, directly linked to the 
medical records (Cobas, 2018).  
Self-monitoring 
Within the community setting routine self-monitoring of blood glucose levels is advised for all 
people with T1DM, ideally at least 4 times per day; before each meal and before bed (NICE, 
2015a). People with T2DM can also self-monitor blood glucose if they require insulin, have 
evidence of hypoglycaemia, or if pregnant or planning pregnancy (NICE, 2015c).   
Technologies are available which now enable people with diabetes to continuously monitor 
and manage their blood glucose and review results via mobile devices. In November 2017, the 
Abbott Freestyle Libre continuous glucose monitor device was made available through the 
NHS formulary for people with T1DM who meet specific criteria. The device continuously 
measures glucose levels within interstitial fluid, utilising a sensor applied to the skin (NICE, 
(2017). These devices will become increasingly prevalent in coming years.  
Consideration should be given when people who routinely monitor their own blood glucose 
are admitted to hospital. There is conflicting evidence as to the continuation of self-monitoring 
in the in-patient setting. Whilst some authors highlight the complexity of hospital treatment 
and its effect on normal glucose control as a factor which makes self-monitoring beyond the 
ability of the individual to manage their own blood glucose (Shah and Rushakoff, 2015); others 
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counter this argument highlighting that removing self-monitoring may place the person at 
increased risk of hypo or hyperglycaemia (Mabrey and Setji, 2015).  
However, there is consensus that cooperative management and partnership with people with 
diabetes should be encouraged to maximise satisfaction and clinical outcome.  
Recommendations and developments:  
Timely internal quality control including unit calibration must be carried out as per local policy 
and manufacturer’s guidance to ensure the device is working correctly and results are reliable. 
External quality assessment (EQA) should also be implemented using the analysis of 
standardised test samples with an undisclosed value from an external source. Participation in 
an EQA scheme allows comparability across sites and can often be coordinated through 
laboratory departments (MHRA, 2013). Holt, Kumar and Watkins (2013) suggest the use of 
technologies that utilise existing wireless POC testing to integrate with a diabetes data 
management system to proactively institute timely changes in diabetic management. Electronic 
prescribing further enhances this safety focus.   
Conclusion:  
All nurses should be familiar with the importance of blood glucose monitoring and the 
procedure to carry out testing safely and effectively. Appropriate and timely monitoring of 
blood glucose will allow for the appropriate management of blood glucose, which falls out of 
target ranges. This will ensure ongoing safety during episodes of acute illness or effective 
management of diabetes mellitus in the longer term, minimising future diabetic related health 
complications.  
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